(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

Ionis Presents Positive Phase 2 Data from Donidalorsen Open-Label Extension Study at the 2022 ACAAI Annual Meeting | BioSpace

Interim Results Show Sustained Reduction in Hereditary Angioedema Attacks and No New Safety Signals in Patients Treated for One Year CARLSBAD, Calif., Nov. 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense drug, donidalorsen, …

Ionis Presents Positive Phase 2 Data from Donidalorsen Open-Label Extension Study at the 2022 ACAAI Annual Meeting | BioSpace Read More »